| Literature DB >> 30607330 |
Sina Mojaverrostami1, Maryam Nazm Bojnordi2,3, Maryam Ghasemi-Kasman4, Mohammad Ali Ebrahimzadeh5, Hatef Ghasemi Hamidabadi2,6.
Abstract
Multiple sclerosis is a complex autoimmune disorder which characterized by demyelination and axonal loss in the central nervous system (CNS). Several evidences indicate that some new drugs and stem cell therapy have opened a new horizon for multiple sclerosis treatment, but current therapies are partially effective or not safe in the long term. Recently, herbal therapies represent a promising therapeutic approach for multiple sclerosis disease. Here, we consider the potential benefits of some herbal compounds on different aspects of multiple sclerosis disease. The medicinal plants and their derivatives; Ginkgo biloba, Zingiber officinale, Curcuma longa, Hypericum perforatum, Valeriana officinalis, Vaccinium macrocarpon, Nigella sativa,Piper methysticum, Crocus sativus, Panax ginseng, Boswellia papyrifera, Vitis vinifera, Gastrodia elata, Camellia sinensis, Oenothera biennis, MS14 and Cannabis sativa have been informed to have several therapeutic effects in MS patients.Entities:
Keywords: Demyelination; Herbal therapy; Inflammation; Multiple sclerosis; Remyelination
Year: 2018 PMID: 30607330 PMCID: PMC6311642 DOI: 10.15171/apb.2018.066
Source DB: PubMed Journal: Adv Pharm Bull ISSN: 2228-5881
Summary of herbal medicines used in the treatment of Multiple sclerosis
|
|
|
|
|
|
|
|
|
|
| Johnson et al (USA) | Clinical trial-Double-blind, placeo-controlled | 240 mg/day of ginkgo extract | 22 MS patients | 4 weeks | Treatment with ginkgo extract relieved fatigue with no adverse effect in MS patients | 34 |
| Lovera et al (USA) | Clinical trial-Double-blind, placeo-controlled | 240 mg/day of ginkgo extract | 38 MS patients | 12 weeks | Improvement of the cognitive performance were reported in treated group | 37 | |
| Brochet et al (France) | Clinical trial-Double-blind, placeo-controlled | 240 and 360 mg/day of ginkgolide B | 104 MS patients | 1 week | ginkgolide B was not an effective treatment for exacerbations of MS | 180 | |
|
| Jafarzadeh et al (Iran) | EAE model of MS in mice | 200 and 300 mg/kg ginger extract | 24 | 4 weeks | Ginger extract ameliorated EAE severity and modulated the expression of IL-27, IL-33 | 43 |
|
| Xie et al (Japan) | EAE model of MS in rats | 100 and200 mg/kg curcumin extract | 21 | 2 weeks | Curcumin decreased the inflammation and the severity of EAE | 53 |
| Natarajan and Bright (USA) | EAE model of MS in SJL/J mice | 50 and 100 µg curcumin in 25 µl DMSO / day | - | 4 weeks | Curcumin decreased CNS inflammation and demyelination also,decreased the severity of EAE | 54 | |
| Mohajeri et al (Iran) | EAE model of MS in rats | 12.5 mg/kg of curcumin | 20 | 17 days | Treatment with polymerized nano-curcumin decreased the severity of EAE and increased the remyelination | 23 | |
|
| Firouzi et al (Iran) | Double blind, randomized clinical trial | 18–21 g/day Evening primrose oil and | 100 MS patients | 24 weeks | Treatment with co-supplemented | 158 |
| Horrobin (Canada) | Double blind, randomized clinical trial | - | 14 MS patients | 24 weeks | Treatment with colchicine and evening primrose oil improved manual dexterity test and clinical score in MS patients | 159 | |
|
| Naziroglu et al (Turkey) | In-vitro study on neutrophils of MS patients | 20 μM/ml | 9 MS patients | - | Treatment with | 69 |
|
| Gallien et al (France) | Double blind, clinical trial, placebo-controlled | 36 mg/day Cranberry extract(proanthocyanidins) | 171 MS patients | 1 year | Treatment with cranberry extract versus placebo did not prevent UTI occurrence in MS patients | 81 |
|
| Fahmy et al (Egypt) | EAE model of MS in rats | 2.8 g/kg | 22 | 4 weeks |
| 85 |
| Noor et al (Egypt) | EAE model of MS in rats | 2.8 g/kg | 22 | 4 weeks |
| 87 | |
|
| Ghaffari et al (Iran) | EAE model of MS in rats | Intrahippocampal (5and 10 μg/rat) injection of the saffron | 35 | 3 days | Local injection of saffron extract modulated the oxidative stress markers (reduced the activity of GPx and SOD enzymes), through scavenging of ROS | 103 |
| Ghazavi et al (Iran) | EAE model of MS in C57bl/6 mice | 100 µL saffron extract | 20 | 3 weeks | Treatment with saffron decreased inflammation in the spinal cord and decreased the severity of EAE | 102 | |
|
| Hwang et al (Korea) | EAE model of MS in C57bl/6 mice | 200 μg of an acidic polysaccharide of | - | 33 days | Acidic polysaccharide of | 113 |
| Etemadifar et al (Iran) | Randomized Double-blind, placeo-controlled | 250 mg ginseng tablets | 52 MS patients | 12 weeks | Ginseng treatment had no adverse effect on MS patients as well as reduced fatigue and had a positive effect on quality of life | 114 | |
|
| Sedighi et al (Iran) | Randomized, double-blinded, placebo-controlled study | 600 mg of | 80 MS patients | 8 weeks |
| 124 |
|
| Sato et al (USA) | EAE model of MS in C57bl/6 mice | 20 mg/kg per day | - | 8 weeks | Resveratrol treatment worsened the demyelination and inflammation without neuroprotective effects in the CNS | 129 |
| Kelly et al (USA) | EAE model of MS in C57bl/6 mice | 100 and 250 mg/kg Sigma resveratrol | - | 4 weeks | Resveratrol delayed the onset of EAE and had a significant neuroprotective effect as well as prevents neuronal loss | 130 | |
| Shindler et al (USA) | EAE model of MS in SJL/J mice | 500 and 1000 mg/kg resveratrol | 62 | 4 weeks | Resveratrol treatment prevented neuronal loss during optic neuritis and reduced neurological dysfunction during EAE | 131 | |
|
| Mahler et al (Germany) | Randomized, double-blinded, placebo-controlled study | 600 mg/d EGCG | 18 MS patients | 12 weeks | Treatment with EGCG improved muscle metabolism during moderate exercise in MS patients | 155 |
|
| Tafreshi et al (Iran) | EAE model of MS in C57bl/6 mice | MS14 containing 30% of the diet | 14 | 20 days |
| 163 |
| Kalan et al (Iran) | EAE model of MS in C57bl/6 mice | MS14 containing 30% of the diet | 25 | 35 days | MS14 decreased EAE symptoms and lymphocyte infiltration into the CNS | 164 | |
| Kalan et al (Iran) | EAE model of MS in C57bl/6 mice | MS14 containing 30% of the diet | 25 | 35 days | Treatment with MS14 reduced clinical signs of EAE, demyelination and IL-6 production | 165 | |
|
| Zajicek et al (UK) | Randomized, placebo-controlled trial | Capsules containing 2.5 mg of THC and 1.25 mg of cannabidiol | 630 MS patients | 15 weeks | cannabinoids improved patients' mobility and improved in spasticity | 173 |
| Zajicek et al (UK) | Double blind, placebo controlled, phase III study | Capsules containing cannabidiol 0.8–1.8 mg and 2.5 mg THC | 279 MS patients | 12 weeks | Treatment with cannabinoids improved the relief from muscle stiffness in MS patients | 172 | |
| Wade et al (UK) | Double-blind, randomized, placebo-controlled study | 120 mg cannabidiol and 120 mg THC | 160 MS patients | 10 weeks | Treatment with cannabinoids improved patient's spasticity, without any adverse effects | 174 | |
| Greenberg et al (USA) | Double-blind, randomized, placebo-controlled study | Smoking one marijuana cigarette containing 1.54% THC | 10 MS patients | 3 days | Smoking marijuana improved eyes-open and eyes-closed tests, and noise variance values | 178 | |
| Brady et al (USA) | Open-label, pilot study | 2.5 mg of THC and 2.5 mg | 10 MS patients | 8 weeks | Cannabinoids decreased urinary | 179 |
Use of herbal medicines in Multiple sclerosis, according to the symptomatic problems
|
|
|
|
|
|
| 69,101 |
|
|
| 73,93 |
|
|
| 36,124 |
|
|
| 79,179 |
|
|
| 114,34 |
|
|
| 33,34,87,101,113,124,130,140,134,159,164,167 |